TheraRadar
← Back
Data updated: Jun 28, 2026

SOLA PHARMS

Generics

SOLA PHARMS is a generic drug manufacturer focused on Neurology.

2020
Since
4
Drugs
-
Trials
0
New Drugs (2yr)

SOLA PHARMS's Key Drugs

SOLA PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

SOLA PHARMS's Recent FDA Approvals

New NDA/BLA approvals for SOLA PHARMS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

SOLA PHARMS's Therapeutic Areas

SOLA PHARMS's approved drugs and pipeline span 1 therapeutic area, led by Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 100%
1 drugs

SOLA PHARMS's Top Competitors

SOLA PHARMS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

SOLA PHARMS Pipeline Snapshot

Active clinical trials for SOLA PHARMS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Neurology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling